Anti Asthma Drugs Market Research Report – Global Forecast to 2027

Anti-Asthma Drugs Market Information, by     Type of Asthma (Allergic (Extrinsic) and Non-Allergic (Intrinsic) Asthma), by Asthma Trigger Type (Child-Onset Asthma, Adult-Onset Asthma, Exercise-Induced Asthma, Cough-Induced Asthma, Occupational Asthma, Nocturnal Asthma, Steroid-Resistant Asthma (Severe Asthma)), by Drug Class (Bronchodilators (Beta Agonists, Anti-Cholinergics, Xanthines), Leukotriene Antagonists, Mast Cell Stabilizers,  Corticosteroids, Monoclonal Antibody), by Therapy (Reliever Treatment and Maintena...

ID: MRFR/Pharma/1736-HCR | February 2021 | Region: Global | 85 pages         

Anti Asthma Drugs Market

The Anti Asthma Drugs Market Share is expected to reach USD 28.3 billion at a CAGR of 5.94% during the forecast period.

Segmentation

By Type of Asthma Allergic Non-Allergic
By Asthma Trigger Type Child-Onset Asthma Adult-Onset Asthma Exercise-Induced Asthma Cough-Induced Asthma Occupational Asthma Nocturnal Asthma Steroid-Resistant Asthma
By Drug Class Bronchodilators Leukotriene Antagonists Mast Cell Stabilizers
By Therapy Reliever Treatment Maintenance Treatment
By Route of Administration Oral Inhaled Intravenous Subcutaneous

Key Players

  • GlaxoSmithKline plc.
  • Merck & Co. Inc.
  • AstraZeneca plc.
  • Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries
  • Innoviva Inc.
  • Novartis International AG
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A.
  • Sunovion Pharmaceuticals Inc.

Drivers

  • Increase in patients due to increased pollution
  • Growing awareness of the benefits of modern drug therapy.
Speak to Analyst Request a Free Sample

Anti Asthma Drugs Market Overview


The anti asthma drugs market size is expected to reach approximately, 300 Million people suffering from asthma during the historic forecast period and the figures are mounting which is blamed on increased pollution and unhealthy lifestyles. The Anti Asthma Drugs Market Share is expected to reach USD 28.3 billion at a CAGR of 5.94%  during the forecast period. Asthma is a chronic lung illness marked by hyperresponsiveness of the tracheobronchial smooth muscle to stimuli, resulting in air tube restriction and inflammation, as well as increased secretion, edema, and fluid build-up. Tightness in the chest, wheezing, coughing, and possible limitations in activities due to breathing difficulties are some of the symptoms. The anti-asthmatics pharmaceuticals market includes sales of anti-asthmatics drugs by companies that make them. Manufacturers of anti-asthmatic medications such as bronchodilators, anti-inflammatory pharmaceuticals, monoclonal antibodies, and combination therapies make up the anti-asthmatics drug sector. Asthma is a disorder that causes the body's airways to restrict, swell, and produce excess mucus. Coughing, wheezing on exhale, and shortness of breath can occur as a result of this.


COVID Analysis


According to a study published in the European Respiratory Journal during the historic forecast period by José Luis Izquierdo, allergy-related variables such as rhinitis and eczema were less common in asthmatic patients with COVID-19. These comorbidities were found to be very common in COVID-19 individuals who needed to be admitted to the hospital. Furthermore, when compared to non-hospitalized patients, the use of inhaled corticosteroids (ICS) was lower in individuals who required hospitalization due to COVID-19. Even though patients treated with biologics had higher severity and more comorbidities in the ear, nose, and throat, COVID-19-related hospitalizations were quite low in these patients. As a result of comorbidity-related characteristics, patients with asthma and COVID-19 were older and at higher risk.


When COVID-19 strikes, patients with chronic obstructive pulmonary disease (COPD) are at a higher risk of severe pneumonia and poor outcomes. This could be due to a lack of underlying lung reserves or enhanced ACE-2 receptor expression in narrow airways. There is growing evidence that Asthma may be a risk factor for more severe COVID-19 disease. Even after adjusting for age and smoking, an examination of comorbidities in 1,590 COVID-19 patients across China found that Asthma had an odds ratio of 2.681 for ICU admission, mechanical ventilation, or death. Asthma was present in 62.5% of severe cases (compared to 15.3% in non-severe cases), and Asthma patients made up 25% of those who died (compared with only 2.8% of those who survived). Thus, the Anti Asthma Drugs Market Growth has increased during the pandemic times.


Anti Asthma Drugs Market Dynamics


Drivers


Growing awareness of the benefits of modern drug therapy, a strong pipeline of anti-asthma drugs with some novel molecules, an increase in patients due to increased pollution, and the great potential of biologics, which is expected to dominate the future market, are all factors that favor Anti-Asthma Drugs Market Growth during the Anti Asthma Drugs Market Analysis. The rising prevalence of respiratory disorders, increased incidence of cigarette smoking, global warming, aging population, growing markets, innovative technologies for drug discovery, and an increase in healthcare expenditure have all been growth factors in the past that have changed the Anti Asthma Drugs Market Outlook. It's encouraging to see that we believe the market's growth factors will outweigh the restraints and that the biologics segment's commercialization will propel the Anti Asthma Drugs Market Value forward and increase the Anti Asthma Drugs Market Trends.


Restraints


Loss of patents on top names like Advair and Symbicort, market fragmentation, and generic penetration are all limiting considerations. Side effects connected with respiratory medications, a decline in free trade, and stringent regulations are all factors that could slow the Anti Asthma Drugs Market Value and Anti Asthma Drugs Market Trends in the future. In the projected years, side effects associated with respiratory medicines are expected to impede market expansion. Asthma sufferers are subjected to a variety of respiratory medication adverse effects. Dry mouth, headaches, constipation, fast heartbeat, muscle cramps, and shaking are some of the most common side effects. Inhaled steroids used to treat asthma can cause thrush (a yeast infection in the mouth) and hoarseness in some people. As a result, doctors are increasingly offering alternative therapies to their patients, such as herbs and dietary supplements, yoga, relaxation, and acupuncture. In the forecast period, the Anti Asthma Drugs Market Size is likely to be limited by an increasing preference for alternative therapies for the treatment of asthma during the Anti Asthma Drugs Market Analysis.


Participants in the Global Anti Asthma Drugs Market will benefit from technological advancements and improvements in the coming years. Asthma is getting more common among the world's population even during the COVID era. The installed base of various types of products for the Anti Asthma Drugs Market Analysis has grown as a result of technological developments. An increase in the incidence and prevalence of asthma, technological improvements, and the expanding elderly population are some of the reasons driving the market growth. Furthermore, technological advances are expected to generate profitable prospects for the industry. Traditional therapy limitations, such as late-onset of action and low efficacy, are expected to drive the development of novel targeted drugs, enhancing future Anti-Asthma Drugs Market Outlook.


Anti Asthma Drugs Market Segment Overview


The Global Anti Asthma Drugs Market is further bifurcated into various segments depending on various factors to help the market to grow as per the predicted CAGR growth by the end of the forecast period in 2027. The Global Anti Asthma Drugs Market is segmented based on the following:


Based on the drug class, the market is segmented on the following:



  • Bronchodilators

  • Monoclonal Antibodies

  • Anti-inflammatory Drugs

  • Combination Drugs


Based on the end-user, the market is segmented on the following:



  • Asthma Patients

  • COPD Patients


Based on the distribution channel, the market is segmented on the following:



  • General Pharmacies

  • Hospital Pharmacies

  • Online Retailers

  • Others


Based on the therapy, the market is segmented on the following:



  • Preventive

  • Curative


Based on the route of administration, the market is segmented on the following:



  • Oral

  • Inhaled

  • Intravenous

  • Subcutaneous


Anti Asthma Drugs Market Regional Classification


North America is the world's largest market for anti-asthma drugs. Anti-asthma drugs market has the second-largest market in Europe. The rising frequency of disorders like asthma, the aging population, increased research and development activities, and the existence of important market participants are all contributing to this growth. Because of better screening and distribution of health care facilities, the developing world, particularly the Asia Pacific, is accounting for a large number of novel cases. However, the market in developing regions, particularly the Asia Pacific, will rise at the fastest rate and will be the most important in the future.


Anti Asthma Drugs Market Competitive Landscape


Leading competitors in the Anti Asthma Drug markets are focusing on expanding their operations in emerging markets. The market's players have continually launched novel solutions to expand their product offerings. The two most common growth tactics used by significant market players are product approval and clinical trials. The major key players operating in the global anti-asthma drugs market are



  • GlaxoSmithKline plc.

  • Merck & Co., Inc.

  • AstraZeneca plc.

  • Hoffmann-La Roche Ltd

  • Teva Pharmaceutical Industries

  • Innoviva, Inc.

  • Novartis International AG

  • Boehringer Ingelheim

  • Chiesi Farmaceutici S.p.A.

  • Sunovion Pharmaceuticals Inc.

  • Others


Recent Developments



  • Chiesi Farmaceutici S.p.A. has begun a phase III clinical research (PILASTER study) to assess the efficacy and safety of two doses of CHF6001 (Tanimilast) as an add-on to maintenance triple treatment in patients with Asthma.

  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') from GlaxoSmithKline Plc and Innoviva, Inc. has been approved by the US Food and Drug Administration (FDA) for the treatment of asthma in patients aged 18 and above.


Report Overview


Growth is one of a series of new reports that provides market overviews, analyses, and forecasts market size and growth for the entire market, segments and regions, drivers, restraints, key competitors' revenues, profiles, market shares, and market segments. The influence of COVID-19 on the market is also examined in depth in the research. Based on industry trends and leading rivals' methods, the studies indicate top countries and segments for opportunities and strategies. According to the report, Competitive intelligence identifies the strategies used by prominent market competitors in distinct geographic locations. In this study, key market players in the asthma medicine industry are profiled, and their tactics are thoroughly examined, predicting the competitive picture of the worldwide asthma drug market.



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 28.3 Billion
  CAGR   5.94% (2016-2022)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, trigger, therapy, drug class and by route of administration
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GlaxoSmithKline plc., Merck & Co., Inc., AstraZeneca plc., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries, Novartis International AG, Boehringer Ingelheim, Sunovion Pharmaceuticals Inc.
  Key Market Opportunities   increasing pollution and great potential of biologics which is anticipated to dominate the future
  Key Market Drivers

  • Growing awareness of the benefits of modern drug therapy
  • Strong pipeline of anti-asthma drugs with some novel molecules


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Anti asthma drugs market is valued at USD 28.3 billion by 2022.

    Anti asthma drugs market can expand at 5.94% CAGR from 2015 to 2022.

    Anti asthma drugs market is driven by large number of asthma patients, advantages of modern drug therapy, and potential of biologics.

    Patent expiry of blockbuster drugs is one of the biggest challenges faced by the global anti asthma drugs market.

    The Americas can dominate the global anti asthma drugs market till 2022.

    Novartis International AG, Teva Pharmaceutical Industries, AstraZeneca plc., F. Hoffmann-La Roche Ltd, Boehringer Ingelheim, GlaxoSmithKline plc., Merck & Co., Inc., and Sunovion Pharmaceuticals Inc. are notable players of the global anti asthma drugs market.